Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth
CompanyMedical Device

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth

Bio-Thera's Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
CompanyDrug

Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
CompanyDeals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Henlius Biotech Licenses HLX15 to Dr. Reddy's for US and European Markets
CompanyDeals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches
Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

CanSino's Tetanus Vaccine NDA Accepted for Review by NMPA
CompanyDrug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
CompanyDrug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer's Disease
CompanyDrug

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
CompanyDrug

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
CompanyDrug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
CompanyDrug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer